WELBIO is an inter-university life sciences research institute based in Wallonia, Belgium. WELBIO is funded by the Walloon Region. Our mission is to support strategic fundamental research through carefully selected projects from universities in the Wallonia-Brussels Federation, with a view to transforming their discoveries into industrial applications in all fields of biotechnology.

Discovery of a tumour cell population responsible for resistance to therapy and tumour relapse in the most frequent human cancer.

Researchers lead by Pr. Cédric Blanpain, MD/PhD, WELBIO investigator and Professor at the Université Libre de Bruxelles, Belgium, identified a population of tumour cells that persist following drug treatment, leading to cancer relapse following treatment discontinuation in basal cell carcinoma, the most frequent skin cancer. The study also identifies a combination of drugs that can eliminate the tumour population that resists to the therapy and prevents tumour relapse after treatment discontinuation. The results of this study have been published in Nature.

WELBIO about to celebrate its 10th anniversary.

This 10th anniversary is the right time for evaluation as the Walloon Government must decide about its budget.

Alban de Kerchove d'Exaerde laureate of the 4th triennial prize of the Clerdent Foundation.

Dr Alban de Kerchove d'Exaerde WELBIO Investigator at the Université libre de Bruxelles is the 2018 winner of the triennial prize awarded by the Pierre and Simone Clerdent Foundation.

All news

Last update : 20/4/2018 - Vie privée - Printable version -  © 2018 WELBIO

Home Login